Advanced search
Publication Cover
Emerging Microbes & Infections Volume 5, 2016 - Issue 1
Submit an article Journal homepage
1,576
Views
38
CrossRef citations to date
0
Altmetric
Reviews

Entry inhibitors: New advances in HCV treatment

Xi-Jing QianShanghai Key Laboratory of Medical Biodefense, Department of Microbiology, Second Military Medical University, Shanghai200433, China
,
Yong-Zhe ZhuShanghai Key Laboratory of Medical Biodefense, Department of Microbiology, Second Military Medical University, Shanghai200433, China
,
Ping ZhaoShanghai Key Laboratory of Medical Biodefense, Department of Microbiology, Second Military Medical University, Shanghai200433, China
&
Zhong-Tian QiShanghai Key Laboratory of Medical Biodefense, Department of Microbiology, Second Military Medical University, Shanghai200433, ChinaCorrespondence[email protected]
Pages 1-8 | Received 10 Sep 2015, Accepted 02 Nov 2015, Published online: 25 Jan 2019

  • LavanchyD.The global burden of hepatitis C.Liver Int2009; 29:74–81.
  • AlterMJ.Epidemiology of hepatitis C virus infection.World J Gastroenterol2007; 13:2436–2441.
  • GhanyMG,StraderDB,ThomasDL,SeeffLB,American Association for the Study of LiverD.Diagnosis, management, and treatment of hepatitis C: an update.Hepatology2009; 49:1335–1374.
  • LiangTJ,GhanyMG.Current and future therapies for hepatitis C virus infection.N Engl J Med2013; 368:1907–1917.
  • MederackeI,Von HahnT.Survival of the fittest: selection of hepatitis C virus variants during liver graft reinfection.Hepatology2011; 53:705–708.
  • BuhlerS,BartenschlagerR.New targets for antiviral therapy of chronic hepatitis C.Liver Int2012; 32:9–16.
  • AghemoA,De FrancescoR.New horizons in hepatitis C antiviral therapy with direct-acting antivirals.Hepatology2013; 58:428–438.
  • GaneEJ,StedmanCA,HylandRHet al.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.N Engl J Med2013; 368:34–44.
  • IssurM,GotteM.Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.Viruses2014; 6:4227–4241.
  • AlqahtaniSA,AfdhalN,ZeuzemSet al.Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials.Hepatology2015; 62:25–30.
  • KlibanovOM,GaleSE,SantevecchiB.Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.Ann Pharmacother2015; 49:566–581.
  • DeeksED.Ombitasvir/paritaprevir/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection.Drugs2015; 75:1027–1038.
  • A 4-drug combination (Viekira Pak) for hepatitis C.JAMA.2015; 313:1857–1858.
  • Canadian Agency for Drugs and Technologies in Health.Holkira (ombitasvir/paritaprevir/ritonavir with dasabuvir) and harvoni (ledipasvir/sofosbuvir) for chronic hepatitis C: a review of the clinical evidence. Ottawa: CADTH, 2015.Available at https://www.cadth.ca/sites/default/files/pdf/htis/jan-2015/RC0632%20Holkira%20and%20Harvoni%20Final.pdf (accessed 16 Jan 2015).
  • KeatingGM.Ledipasvir/sofosbuvir: a review of its use in chronic hepatitis C.Drugs2015; 75:675–685.
  • TemesgenZ,RizzaSA.Daclatasvir for the treatment of chronic hepatitis C virus infection.Drugs Today (Barc)2015; 51:277–288.
  • KowdleyKV,LawitzE,CrespoIet al.Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.Lancet2013; 381:2100–2107.
  • LawitzE,LalezariJP,HassaneinTet al.Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.Lancet Infect Dis2013; 13:401–408.
  • SarrazinC,HezodeC,ZeuzemS,PawlotskyJM.Antiviral strategies in hepatitis C virus infection.J Hepatol2012; 56:S88–100.
  • BarthH,SchaferC,AdahMIet al.Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate.J Biol Chem2003; 278:41003–41012.
  • BarthH,SchnoberEK,ZhangFet al.Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction.J Virol2006; 80:10579–10590.
  • JiangJ,CunW,WuX,ShiQ,TangH,LuoG.Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate.J Virol2012; 86:7256–7267.
  • MolinaS,CastetV,Fournier-WirthCet al.The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus.J Hepatol2007; 46:411–419.
  • AlbeckaA,BelouzardS,Op de BeeckAet al.Role of low-density lipoprotein receptor in the hepatitis C virus life cycle.Hepatology2012; 55:998–1007.
  • SyedGH,TangH,KhanM,HassaneinT,LiuJ,SiddiquiA.Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.J Virol2014; 88:2519–2529.
  • HelleF,WychowskiC,Vu-DacN,GustafsonKR,VoissetC,DubuissonJ.Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.J Biol Chem2006; 281:25177–25183.
  • KhanalM,BarrasA,VausselinTet al.Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry.Nanoscale2015; 7:1392–1402.
  • HolmskovU,ThielS,JenseniusJC.Collections and ficolins: humoral lectins of the innate immune defense.Annu Rev Immunol2003; 21:547–578.
  • HamedMR,BrownRJ,ZothnerCet al.Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.J Innate Immun2014; 6:676–684.
  • CiesekS,von HahnT,ColpittsCCet al.The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.Hepatology2011; 54:1947–1955.
  • CallandN,AlbeckaA,BelouzardSet al.(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.Hepatology2012; 55:720–729.
  • CallandN,SahucME,BelouzardSet al.Polyphenols inhibit hepatitis C virus entry by a new mechanism of action.J Virol2015; 89:10053–10063.
  • RedwanEM,UverskyVN,El-FakharanyEM,Al-MehdarH.Potential lactoferrin activity against pathogenic viruses.C R Biol2014; 337:581–595.
  • El-FakharanyEM,SanchezL,Al-MehdarHA,RedwanEM.Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study.Virol J2013; 10:199.
  • RedwanEM,El-FakharanyEM,UverskyVN,LinjawiMH.Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus.BMC Complement Altern Med2014; 14:219.
  • HongW,LangY,LiTet al.A p7 ion channel-derived peptide inhibits hepatitis C virus infection in vitro.J Biol Chem2015; 290:23254–23263.
  • VanCompernolleSE,WiznyciaAV,RushJR,DhanasekaranM,BauresPW,ToddSC.Small molecule inhibition of hepatitis C virus E2 binding to CD81.Virology2003; 314:371–380.
  • BrimacombeCL,GroveJ,MeredithLWet al.Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.J Virol2011; 85:596–605.
  • LavilletteD,TarrAW,VoissetCet al.Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.Hepatology2005; 41:265–274.
  • GottweinJM,ScheelTK,JensenTBet al.Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.Hepatology2009; 49:364–377.
  • VanwolleghemT,BukhJ,MeulemanPet al.Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain.Hepatology2008; 47:1846–1855.
  • MeulemanP,HesselgesserJ,PaulsonMet al.Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo.Hepatology2008; 48:1761–1768.
  • JiC,LiuY,PamulapatiCet al.Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody.Hepatology2015; 61:1136–1144.
  • MolinaS,CastetV,Pichard-GarciaLet al.Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.J Virol2008; 82:569–574.
  • HsuM,ZhangJ,FlintMet al.Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.Proc Natl Acad Sci USA2003; 100:7271–7276.
  • WakitaT,PietschmannT,KatoTet al.Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.Nat Med2005; 11:791–796.
  • ZhongJ,GastaminzaP,ChengGet al.Robust hepatitis C virus infection in vitro.Proc Natl Acad Sci USA2005; 102:9294–9299.
  • KapadiaSB,BarthH,BaumertT,McKeatingJA,ChisariFV.Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I.J Virol2007; 81:374–383.
  • CaiZ,CaiL,JiangJ,ChangKS,van der WesthuyzenDR,LuoG.Human serum amyloid A protein inhibits hepatitis C virus entry into cells.J Virol2007; 81:6128–6133.
  • LavieM,VoissetC,Vu-DacNet al.Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system.Hepatology2006; 44:1626–1634.
  • ZeiselMB,KoutsoudakisG,SchnoberEKet al.Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.Hepatology2007; 46:1722–1731.
  • BartoschB,VerneyG,DreuxMet al.An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.J Virol2005; 79:8217–8229.
  • CataneseMT,GrazianiR,von HahnTet al.High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.J Virol2007; 81:8063–8071.
  • LacekK,VercauterenK,GrzybKet al.Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.J Hepatol2012; 57:17–23.
  • MassonD,KosekiM,IshibashiMet al.Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.Arterioscler Thromb Vasc Biol2009; 29:2054–2060.
  • SyderAJ,LeeH,ZeiselMBet al.Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.J Hepatol2011; 54:48–55.
  • ZhuH,Wong-StaalF,LeeHet al.Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.J Infect Dis2012; 205:656–662.
  • SulkowskiMS,KangM,MatiningRet al.Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.J Infect Dis2014; 209:658–667.
  • SiY,LiuS,LiuXet al.A human claudin-1-derived peptide inhibits hepatitis C virus entry.Hepatology2012; 56:507–515.
  • KriegerSE,ZeiselMB,DavisCet al.Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.Hepatology2010; 51:1144–1157.
  • FofanaI,KriegerSE,GrunertFet al.Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.Gastroenterology2010; 139:953–964 ,964 e951–954.
  • MaillyL,XiaoF,LupbergerJet al.Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.Nat Biotechnol2015; 5:549–54.
  • LupbergerJ,ZeiselMB,XiaoFet al.EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.Nat Med2011; 17:589–595.
  • MartinDN,UprichardSL.Identification of transferrin receptor 1 as a hepatitis C virus entry factor.Proc Natl Acad Sci USA2013; 110:10777–10782.
  • Del CampoJA,RojasA,Romero-GomezM.Entry of hepatitis C virus into the cell: a therapeutic target.World J Gastroenterol2012; 18:4481–4485.
  • SainzBJr,BarrettoN,MartinDNet al.Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.Nat Med2012; 18:281–285.
  • BlanchardAA,WatsonPH,ShiuRPet al.Differential expression of claudin 1, 3, and 4 during normal mammary gland development in the mouse.DNA Cell Biol2006; 25:79–86.
  • BlaisingJ,LevyPL,PolyakSJ,StaniferM,BoulantS,PecheurEI.Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking.Antiviral Res2013; 100:215–219.
  • MeertensL,BertauxC,DragicT.Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles.J Virol2006; 80:11571–11578.
  • BlanchardE,BelouzardS,GoueslainLet al.Hepatitis C virus entry depends on clathrin-mediated endocytosis.J Virol2006; 80:6964–6972.
  • TscherneDM,JonesCT,EvansMJ,LindenbachBD,McKeatingJA,RiceCM.Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry.J Virol2006; 80:1734–1741.
  • BoriskinYS,LenevaIA,PecheurEI,PolyakSJ.Arbidol: a broad-spectrum antiviral compound that blocks viral fusion.Curr Med Chem2008; 15:997–1005.
  • Chamoun-EmanuelliAM,PecheurEI,SimeonRL,HuangD,CremerPS,ChenZ.Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes.Antimicrob Agents Chemother2013; 57:2571–2581.
  • St VincentMR,ColpittsCC,UstinovAVet al.Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses.Proc Natl Acad Sci USA2010; 107:17339–17344.
  • ColpittsCC,UstinovAV,EpandRF,EpandRM,KorshunVA,SchangLM.5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses.J Virol2013; 87:3640–3654.
  • WolfMC,FreibergAN,ZhangTet al.A broad-spectrum antiviral targeting entry of enveloped viruses.Proc Natl Acad Sci USA2010; 107:3157–3162.
  • PolyakSJ,MorishimaC,ShuhartMC,WangCC,LiuY,LeeDY.Inhibition of T-cell inflammatory cytokines, hepatocyte NF-κB signaling, and HCV infection by standardized Silymarin.Gastroenterology2007; 132:1925–1936.
  • WagonerJ,NegashA,KaneOJet al.Multiple effects of silymarin on the hepatitis C virus lifecycle.Hepatology2010; 51:1912–1921.
  • VausselinT,CallandN,BelouzardSet al.The antimalarial ferroquine is an inhibitor of hepatitis C virus.Hepatology2013; 58:86–97.
  • MatsumuraT,HuZ,KatoTet al.Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry.Gastroenterology2009; 137:673–681.
  • HaidS,NovodomskaA,GentzschJet al.A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes.Gastroenterology2012; 143:213–222 e215.
  • LinLT,ChungCY,HsuWCet al.Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.J Hepatol2015; 62:541–548.
  • YuF,WangQ,ZhangZet al.Development of oleanane-type triterpenes as a new class of HCV entry inhibitors.J Med Chem2013; 56:4300–4319.
  • BlanchetM,SureauC,GuevinC,SeidahNG,LabonteP.SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection.Antiviral Res2015; 115:94–104.
  • LiuS,ChenR,HagedornCH.Tannic acid inhibits hepatitis C virus entry into Huh7.5 Cells.PloS One2015; 10:e0131358.
  • HsuWC,ChangSP,LinLCet al.Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry.Antiviral Res2015; 118:139–147.
  • HeS,LinB,ChuVet al.Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.Sci Transl Med2015; 7:282–249.
  • DescampsV,HelleF,LouandreCet al.The kinase-inhibitor sorafenib inhibits multiple steps of the hepatitis C virus infectious cycle in vitro.Antiviral Res2015; 118:93–102.
  • YinP,ZhangL.Aspirin inhibits hepatitis C virus entry by downregulating claudin-1.J Viral Hepat2015Aug 20. doi: 10.1111/jvh.12446.
  • KoutsoudakisG,KaulA,SteinmannEet al.Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses.J Virol2006; 80:5308–5320.
  • KhanN,MukhtarH.Tea polyphenols for health promotion.Life Sci2007; 81:519–533.
  • Halegoua-De MarzioD,KraftWK,DaskalakisC,YingX,HawkeRL,NavarroVJ.Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract.Clin Ther2012; 34:2279–2285 e2271.
  • Garcia-MontoyaIA,CendonTS,Arevalo-GallegosS,Rascon-CruzQ.Lactoferrin a multiple bioactive protein: an overview.Biochim Biophys Acta2012; 1820:226–236.
  • GentzschJ,BrohmC,SteinmannEet al.Hepatitis C virus p7 is critical for capsid assembly and envelopment.PLoS Pathog2013; 9:e1003355.
  • SteinmannE,PietschmannT.Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy.Viruses2010; 2:2078–2095.
  • OrenR,TakahashiS,DossC,LevyR,LevyS.TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins.Mol Cell Biol1990; 10:4007–4015.
  • LevyS,ShohamT.The tetraspanin web modulates immune-signalling complexes.Nat Rev Immunol2005; 5:136–148.
  • BoucheixC,RubinsteinE.Tetraspanins.Cell Mol Life Sci2001; 58:1189–1205.
  • BaughJM,Garcia-RiveraJA,GallayPA.Host-targeting agents in the treatment of hepatitis C: a beginning and an end?Antiviral Res2013; 100:555–561.
  • PerraultM,PecheurEI.The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.Biochem J2009; 423:303–314.
  • CataneseMT,AnsuiniH,GrazianiRet al.Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.J Virol2010; 84:34–43.
  • BaranovaIN,VishnyakovaTG,BocharovAVet al.Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases.J Biol Chem2005; 280:8031–8040.
  • CaiL,de BeerMC,de BeerFC,van der WesthuyzenDR.Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake.J Biol Chem2005; 280:2954–2961.
  • FarquharMJ,HuK,HarrisHJet al.Hepatitis C virus induces CD81 and claudin-1 endocytosis.J Virol2012; 86:4305–4316.
  • HarrisHJ,FarquharMJ,MeeCJet al.CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry.J Virol2008; 82:5007–5020.
  • HarrisHJ,DavisC,MullinsJGet al.Claudin association with CD81 defines hepatitis C virus entry.J Biol Chem2010; 285:21092–21102.
  • EvansMJ,von HahnT,TscherneDMet al.Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.Nature2007; 446:801–805.
  • FuruseM,FujitaK,HiiragiT,FujimotoK,TsukitaS.Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin.J Cell Biol1998; 141:1539–1550.
  • HaidS,GretheC,DillMT,HeimM,KaderaliL,PietschmannT.Isolate-dependent use of claudins for cell entry by hepatitis C virus.Hepatology2014; 59:24–34.
  • PlossA,EvansMJ,GaysinskayaVAet al.Human occludin is a hepatitis C virus entry factor required for infection of mouse cells.Nature2009; 457:882–886.
  • DornerM,HorwitzJA,RobbinsJBet al.A genetically humanized mouse model for hepatitis C virus infection.Nature2011; 474:208–211.
  • DornerM,HorwitzJA,DonovanBMet al.Completion of the entire hepatitis C virus life cycle in genetically humanized mice.Nature2013; 501:237–241.
  • SendiH,Mehrab-MohseniM,FoureauDMet al.MiR-122 decreases HCV entry into hepatocytes through binding to the 3’ UTR of OCLN mRNA.Liver Int2015; 35:1315–1323.
  • DiaoJ,PantuaH,NguHet al.Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry.J Virol2012; 86:10935–10949.
  • FujitaN,HoriikeS,SugimotoRet al.Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.Free Radic Biol Med2007; 42:353–362.
  • FujitaN,SugimotoR,UrawaNet al.Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.J Gastroenterol Hepatol2007; 22:1886–1893.
  • KaitoM.Molecular mechanism of iron metabolism and overload in chronic hepatitis C.J Gastroenterol2007; 42:96–99.
  • YuL.The structure and function of Niemann-Pick C1-like 1 protein.Curr Opin Lipidol2008; 19:263–269.
  • AltmannSW,DavisHRJr,ZhuLJet al.Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption.Science2004; 303:1201–1204.
  • JiaL,BettersJL,YuL.Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.Annu Rev Physiol2011; 73:239–259.
  • BrooksMJ,BurtsevaEI,ElleryPJet al.Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions.J Med Virol2012; 84:170–181.
  • DeloguI,PastorinoB,BarontiC,NougairedeA,BonnetE,de LamballerieX.In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant.Antiviral Res2011; 90:99–107.
  • HarrisonSC.Viral membrane fusion.Nat Struct Mol Biol2008; 15:690–698.
  • SharmaNR,MateuG,DreuxM,GrakouiA,CossetFL,MelikyanGB.Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion.J Biol Chem2011; 286:30361–30376.
  • PecheurEI,DiazO,MolleJet al.Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis C virus glycoproteins.J Biol Chem2010; 285:25802–25811.
  • HaidS,PietschmannT,PecheurEI.Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles.J Biol Chem2009; 284:17657–17667.
  • BlaisingJ,PecheurEI.Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies.Biochimie2013; 95:96–102.
  • WilhelmS,CarterC,LynchMet al.Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.Nat Rev Drug Discov2006; 5:835–844.
  • FofanaI,JilgN,ChungRT,BaumertTF.Entry inhibitors and future treatment of hepatitis C.Antiviral Res2014; 104:136–142.
  • ZeiselMB,FofanaI,Fafi-KremerS,BaumertTF.Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011; 54:566–576.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.